Yi Boyer Jennifer M sold $70K of INGN

Yi Boyer Jennifer M (EVP Entrprs Enblmnt, Ch HR Off) sold 10,770 shares of Inogen Inc (INGN) at $6.53 on 2026-05-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Yi Boyer Jennifer M
Published Jun 2, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 9:18 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$INGN
Neutral
high confidence
Mentioned
$INGN
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INGNNeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not introduce new company fundamentals, guidance, or external catalysts.

02

Market read

Traders may note the insider sale for sentiment, but the pre-arranged nature limits actionable fundamental implications.

03

What to watch

The sale size is modest relative to typical institutional flows, and the 10b5-1 structure reduces interpretability versus discretionary selling.

Relevance 2/10Novelty 3/10Timing: filed 2026-06-02, transaction dated 2026-05-29

Background

The article is an SEC Form 4 insider transaction disclosure for Inogen, reported via EDGAR.

Company-level read

Ticker impact

$INGNNeutralHigh confidence
Context

Inogen Form 4 shows EVP Yi Boyer Jennifer M sold 10,770 shares at $6.5286 on a 10b5-1 plan, totaling $70,313.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged Rule 10b5-1 plan, and provides no new operating, guidance, or regulatory information.

Market effects

No clear sector read-through; this is company-specific insider trading with no disclosed business change.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with management’s view of near-term valuation risk, so traders may still watch for follow-on selling.

Key entities

  • Inogen Inc

    Subject of the Form 4 insider transaction disclosure.

  • Yi Boyer Jennifer M

    EVP Entrprs Enblmnt, Ch HR Off who executed the sale under a Rule 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$INGNMed

Inogen (INGN) Q3 2026 Earnings Call Transcript

Inogen (INGN) reported Q3 2026 earnings, with total revenue at $77.2M, U.S. sales up 3.8% YoY, and international sales down 9%. The company completed a divestiture of its U.S. oxygen rental business for up to $24.8M. Adjusted net loss was $400K, and a $20M cost savings program was announced to accelerate profitability. New CEO Andrew Reding emphasized growth and operational improvements.

$INGNMed

What Inogen (INGN) Said on Its Q3 Earnings Call

Inogen (INGN) reported Q3 adjusted gross margin decline to 44.2% from 45.9% YoY, citing lower international sales. Operating expenses fell 4.4% to $35.3M. The company sold its U.S. oxygen rental business for up to $24.8M, expecting receipt in 2027. A cost-reduction program targets $20M in annualized savings by 2027. GAAP loss widened to $14.8M from $3.6M YoY. Q4 revenue forecast is $65M-$68M, with full-year revenue expected at $298M-$301M and an adjusted net loss of $7M-$8M.

$INGNMed

Inogen: Q3 Earnings Snapshot

Inogen Inc. (INGN) reported a Q3 loss of $16.2M, or 61 cents per share, with adjusted losses of 56 cents per share. Revenue was $77.2M. The company expects full-year revenue between $298M and $301M.

$INGNLow

Inogen Inc (INGN): Results of Operations and Financial Condition

Inogen Inc (INGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Inogen Announces Leadership Transition Chief Operating Officer Andy Reding Appointed President and Chief Executive Officer BEVERLY, Mass., November 5, 2026 – Inogen, Inc. (Nasdaq: INGN ), a medical technology company offering innovative respiratory products for use i